Oliguria at time of initiating dialysis in critical COVID-19 patients tied to non recovery: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-12-07 03:30 GMT   |   Update On 2021-12-07 06:25 GMT

In critically ill patients with COVID-19, CKD and oliguria at the time of dialysis initiation were each significantly associated with a lower likelihood of kidney recovery, according to a recent study published in the American Journal of Kidney Diseases. Acute kidney injury treated with kidney replacement therapy (AKI-KRT) occurs frequently in critically ill patients with...

Login or Register to read the full article

In critically ill patients with COVID-19, CKD and oliguria at the time of dialysis initiation were each significantly associated with a lower likelihood of kidney recovery, according to a recent study published in the American Journal of Kidney Diseases.

Acute kidney injury treated with kidney replacement therapy (AKI-KRT) occurs frequently in critically ill patients with COVID-19. The researchers examined the clinical factors that determine kidney recovery in this population. The researchers developed a multicenter cohort study.

4221 adults with COVID-19 not receiving kidney replacement therapy who were admitted to intensive care units at 68 US hospitals with COVID-19 from March 1 to June 22, 2020 (the "ICU cohort"). Among these, 876 developed AKI-KRT after admission to the ICU (the "AKI-KRT subcohort"). The ICU cohort was analyzed using AKI severity as the exposure. For the AKI-KRT subcohort, exposures included demographics, comorbidities, initial mode of KRT, and markers of illness severity at the time of dialysis initiation.

The outcome for the ICU cohort was estimated glomerular filtration rate (GFR) at hospital discharge. A three-level outcome including death, kidney nonrecovery, and kidney recovery at discharge, was analyzed for the AKI-KRT subcohort.

The ICU cohort was characterized using descriptive analyses. The AKI-KRT subcohort was characterized with both descriptive analyses and multinomial logistic regression to assess factors associated with kidney nonrecovery while accounting for death.

The Results of the study are as follows:

Among a total of 4221 patients in the ICU cohort, 2361 (56%) developed AKI, including 876 (21%) who received KRT. More severe AKI was associated with higher mortality. Among survivors, more severe AKI was associated with an increased rate of kidney nonrecovery and lower kidney function at discharge. Among the 876 patients with AKI-KRT, 588 (67%) died, 95 (11%) had kidney nonrecovery, and 193 (22%) had kidney recovery by the time of discharge. The odds of kidney nonrecovery was greater for lower estimated GFR with odds ratios (ORs) of 2.09 (95% CI, 1.09-4.04), 4.27 (95% CI, 1.99-9.17), and 8.69 (95% CI, 3.07-24.55) for CKD GFR categories 3, 4, and 5, respectively, compared to estimated GFR > 60 mL/min/1.73 m2. Oliguria at the time of KRT initiation was also associated with nonrecovery (OR 2.10 [95% CI, 1.14-3.88] and 4.02 [95% CI, 1.72-9.39] for patients with 50-499 and <50 mL urine/day respectively, compared to ≥500 mL urine/day)

Thus, the researchers concluded that lower baseline eGFR and reduced urine output at the time of KRT initiation are each strongly and independently associated with kidney nonrecovery among critically ill patients with COVID-19.

Reference:

Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated with Dialysis: The STOP-COVID Cohort Study by Caroline M. Hsu et al. published in the American Journal of Kidney Diseases.

https://doi.org/10.1053/j.ajkd.2021.11.004


Tags:    
Article Source : American Journal of Kidney Diseases.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News